advantages of metronomic chemotherapy in er /her2- metastatic breast cancer
Published 2 years ago • 415 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
1:06
meteora-ii: metronomic vex versus paclitaxel in er /her2- metastatic breast cancer
-
0:53
treating metastatic breast cancer with metronomic vex in the meteora-ii trial
-
1:03
using metronomic chemotherapy as a second-line treatment in head and neck cancer
-
2:14
management of premenopausal hr /her2- breast cancer with micro-metastasis
-
6:28
benefits of metronomic chemotherapy and the aims of the metronomic global health initiative
-
2:09
the evolution of her2 targeting in metastatic breast breast cancer
-
1:17
crsf 2021-hn-001: assessing the use of metronomic chemotherapy in low-income settings
-
6:13
toripalimab plus metronomic chemotherapy show efficacy in treating in her2-negative metastatic b...
-
57:20
metronomic chemotherapy in breast cancer : we are on
-
3:22
managing recurrent metastatic er /her2- breast cancer
-
1:56
dr. chavez mac gregor on chemotherapy in node-positive hr /her2- breast cancer
-
1:29
poziotinib for her2-positive metastatic breast cancer
-
3:08
the benefits of tucatinib in her2 breast cancer
-
20:37
the role of chemotherapy in the treatment of metastatic breast cancer patients
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
1:25
current state of cdk4/6 inhibitors in metastatic her2-negative breast cancer
-
2:10
treating cns metastases in her2 breast cancer
-
1:30
tucatinib in her2 breast cancer with leptomeningeal metastases
-
1:08
the role of immunotherapy in endocrine-refractory luminal breast cancer